T1	Participants 282 495	patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
T2	Participants 831 860	metastatic colorectal cancer.